Summary

Introduction: Acinetobacter species can cause health care-associated infections in patients who are treated in intensive care units of hospitals. The aim of this study was to determine the antibiotic resistance rates of Acinetobacter species that induce health care-associated infections among intensive care unit patients in a state hospital during the period 2008-2011.

Materials and Methods: Clinical samples obtained from intensive care unit patients were cultured by regular methods. The identification and antibiotic susceptibility tests were performed using the BD Phoenix 100 system, BD Phoenix NMIC/ID-82 Id+ADT (Becton Dickinson, Belgium).

Results: During the study period a total of 320 Acinetobacter strains were isolated. Colistin and tigecycline were found to be the most effective antimicrobial agent against Acinetobacter species. When the resistance rates were compared between 2008 and 2011, significant increases were observed for imipenem, meropenem, ceftazidime, trimethoprim-sulfamethoxazole, and ampicillin- sulbactam; a significant decrease was observed for tobramycin. No statistically significant changes were observed for amikacin, cefepime, ceftriaxone, piperacillin-tazobactam, and gentamicin.

Conclusion: High antibiotic resistance rates of Acinetobacter species induce health care- associated infections in intensive care unit patients. It is important to undertake bacteriologic surveillance in hospitals to ascertain the common microorganisms and their antibiotic resistance rates.

Introduction

In this study, it was aimed to determine the antibiotic resistance rates of Acinetobacter strains isolated from clinical specimens of ICU patients and the distribution of these ratios during the period 2008-2011.

Methods

A prospective and active surveillance was performed among patients treated in a state hospital ICU between 2008 and 2011. The diagnosis of health careassociated infection was based on the Centers for Disease Control and Prevention (CDC) criteria[7]. A total of 320 Acinetobacter spp. isolated from the patients who had health care-associated infection in the ICU and the antibiotic resistance of the isolates were investigated in the study. The samples were inoculated on 5% sheep blood agar and EMB agar. The identification and antibiotic susceptibility tests were performed using the BD Phoenix 100 system, BD Phoenix NMIC/ID-82 Id+ADT (Becton Dickinson, Belgium). Strains defined as Acinetobacter spp. were evaluated for resistance to antimicrobials. Statistical analysis was performed with the Statistical Package for the Social Sciences (SPSS) for Windows (SPSS Inc., Chicago, IL, USA) program and the non-parametric chi-square test.

Results

Table 1: The distribution of the Acinetobacter strains

Table 2: The distribution of the samples (%)

We determined the antibiotic resistance rates for a four-year average as follows: 93.4% for ceftazidime, 93.2% for cefepime, 93.1% for ceftriaxone, 92.6% for ciprofloxacin, 91.4% for gentamicin, 89.4% for ampicillin- sulbactam, 88.9% for piperacillin-tazobactam, 88.9% for amikacin, 84.5% for tetracycline, 87.9% for trimethoprim-sulfamethoxazole, 68.5% for meropenem, 67.6% for cefoperazone-sulbactam, 65.8% for imipenem, 37% for tobramycin, 2.5% for colistin, and 10% for tigecycline (Figure 1).

Figure 1: Antibiotic resistance rates of Acinetobacter strains (%).

The annual distribution of these ratios is shown in Table 3. When the resistance rates were compared between 2008 and 2011, significant increases were observed for imipenem (p< 0.001), meropenem (p< 0.001), ceftazidime (p< 0.001), trimethoprim-sulfamethoxazole (p< 0.01), and ampicillin-sulbactam (p< 0.05). Further, significant increases were observed for cefoperazone-sulbactam between 2009 and 2011. Although a significant decrease was observed for tobramycin (p< 0.001), we found no statistically significant changes for amikacin, cefepime, ceftriaxone, piperacillin-tazobactam, and gentamicin (Table 3).

Table 3: Antibiotic resistance rates of Acinetobacter strains between years 2008-2011 (%)

Discussion

Table 4: Antibiotic resistance rates of Acinetobacter strains isolated from various ICU patients (%)

References

1Yavuz MT, Sahin I, Behcet M, Ozturk E, Kaya D. Antibiotic susceptibility of Acinetobacter baumannii strains isolated from various clinical samples. ANKEM 2006;20(Suppl 2):107-10.

2Oncül O. Hastane kaynaklı bakteriyel enfeksiyonlar: In: Willke Topçu A, Söyletir G, Doğanay M (eds). Enfeksiyon Hastaliklari ve Mikrobiyolojisi. 3rd ed. Istanbul: Nobel Tıp Kitabevleri, 2008:575-05.

3Palabıyıkoğlu İ, Bengisun S. In vitro antibiotic susceptibilities in nosocomial Acinetobacter baumannii strains isolated from intensive care unit and other clinics. Turk J Hosp Infect 1999;3:107-10.

4Hartman BJ, Allen DM. Acinetobacter species. In: Mandell GL, Bennett JE, Dolin R (eds). Mandell, Douglas and Bennett’s Principles and Practices of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingstone, 2010:2881-5.

5Runnegar N, Sidjabat H, Goh HM, Nimmo GR, Schembri MA, Peterson DL. Molecular epidemiology of multidrugresistant Acinetobacter baumannii in a single institution over a 10 year period. J Clin Microbiol 2010;48(Suppl 11):4051-6.

6Arman D. Challenges with gram negative bacteria in intensive care unit. ANKEM 2009;23(Suppl 2):146-56.

7Garner JS, Jarvis WR, Emori TG, Horan TC, Huge JM. CDC definitions for nosocomial infections. Am J Infect Control 1988;16:128-40.

8Daughari HJ, Ndakidemi PA, Human IS, Benade S. The ecology, biology, pathogenesis of Acinetobacter spp: an overview. Microbes Environ 2011;26(Suppl 2):101-12.

9Dündar D, Meric M, Baykara N, Willke A. Causative agents of patients from adult intensive care unit of Kocaeli University Hospital and their antimicrobial susceptibilities. Klimik Dergisi 2008;21(Suppl 3):122-5.

10Kiremitci A, Durmaz G, Durmaz A, Akgün Y, Kiraz N, Aybey A, Yelken B. Frequency of isolation and antimicrobial resistance patterns of the microorganisms isolated from various clinical specimens in an anesthesia intensive care unit, data of year 2003. Turk J Infect 2006;20(Suppl 3):37-40.

11Alışkan H, Çolakoğlu, Turunç T, Demiroğlu YZ, Erdoğan F, Akın Ş, Arslan H. Four years monitorization of antibiotic sensitivity rates of Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from patients in intensive care unit and inpatient clinics. Bull Microbiol 2008;42:321-9.

12Ozdemir M, Erayman I, Gundem NS, Baykan M, Baysal B. Investigation of antibiotic susceptibility of Acinetobacter strains in nosocomial infections. ANKEM 2009;23(Suppl 3):127-32.

13Aygun G, Dikmen Y, Mete B, et al. The antibiotic susceptibility of Acinetobacter baumannii strains isolated from nosocomial infections in intensive care unit. ANKEM 2002;16(Suppl 1):85-8.

14Goktas U, Yaman G, Karahocagil MK, Bilici A, Katı İ, Berktas M, Akdeniz H. Evaluation of nosocomial infections and antibiotic resistance profiles in the anesthesiology intensive care unit. Turk J Intensive Care Med 2010;8(Suppl 1):13-7.

15Çetin ES, Kaya S, Pakbas İ, Demirci M. Microorganisms isolated from patients in intensive care units and their antibiotic susceptibilities. Journal of Inonu University Medical Faculty 2007;14(Suppl 2):69-73.

16İnan D, Saba R, Keskin S, Ogünc D, Çiftci C, Gunseren F, Mamıkoglu L, Gultekin M. Nosocomial infections in Akdeniz University Intensive Care Units. Turk J Intensive Care Med 2002;2(Suppl 2):129-35.

17Serefhanoglu K, Turan H, Ergin-Timurkaynak F, Arslan H. Spectrum and antibiotic susceptibility of uropathogens from symptomatic urinary tract infections in a general intensive care unit. Klimik Dergisi 2007;20(Suppl 3):88-91.

18Ozer B, Tatman-Oktun M, Memis D, Otkun M. The nosocomial infections, microorganisms and their antimicrobial susceptibilities and antibiotic consumption in intensive care unit. Turk J Infect 2006;20(Suppl 3):165-70.

19Kuçukbayrak A, Ozdemir D, Sencan İ, Yavuz T, Behcet M, Erdogan S. Intensive care infections at AIBU Düzce Medical Faculty Hospital’s: 2003 years results. Düzce Medical Journal 2004;3:15-9.

20Akkurt L, Havuz SG, Uyar Y, Karadag A, Esen Ş, Günaydın M. Antibiotic resistance in bacteria isolated from intensive care unit in 1999 and 2000 years. ANKEM 2002;16:14-7.

21Kurtoglu MG, Opus A, Kaya M, Kesli R, Güzelant A, Yüksekkaya S. Antimicrobial resistance of Acinetobacter baumannii strains isolated from clinical samples in an education and research hospital (2008-2010). ANKEM 2011;25(Suppl 1):33-41.

22Villalón P, Valdezate S, Medina-Pascual MJ, Rubio V, Vindel A, Saez-Nieto JA. Clonal diversity of nosocomial epidemic Acinetobacter baumannii strains isolated in Spain. J Clin Microbiol 2011;49(Suppl 3):875-82.

23Arda B, Yamazhan T , Ulusoy S , Özinel MA. Yoğun bakım ünitelerinden izole edilen P. aeruginosa ve Acinetobacter türlerinin antibiyotik duyarlılığındaki dört yıllık değişim (1995 ve 1999). Turk J Hosp Infect 2001;5(Suppl 1):49-53.